Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood Cancer

T2Covered by 1 source · first reported by Fierce Biotech / Fierce Healthcare / MedCity / GEN at 19 Oct, 20:27 UTC

The Silence Therapeutics acquisition gives Merck KGaA a drug ready for a pivotal test in the blood disorder polycythemia vera. Silence’s RNA therapy offers a different approach and a potential dosing advantage over a Takeda Pharmaceutical product recently approved in this indication. The post Merck…

businessscience

Sources

• T2Merck KGaA’s $1.1B Silence Therapeutics Buyout Brings RNA Drug for Rare Blood CancerFierce Biotech / Fierce Healthcare / MedCity / GEN19 Oct, 20:27